Dai­ichi Sankyo sets new highs for As­traZeneca-part­nered can­cer drug En­her­tu

New ap­proved in­di­ca­tions and mas­sive year-over-year sales growth has Dai­ichi Sankyo eye­ing a year-end pop in sales for its As­traZeneca-part­nered can­cer drug En­her­tu.

The Japan­ese …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER